Home » Stocks » Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc. (HEPA)

Stock Price: $4.39 USD -0.02 (-0.45%)
Updated Aug 7, 2020 1:32 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 39.62M
Revenue (ttm) n/a
Net Income (ttm) -8.96M
Shares Out 9.03M
EPS (ttm) -10.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $4.39
Previous Close $4.41
Change ($) -0.02
Change (%) -0.45%
Day's Open 4.35
Day's Range 4.33 - 4.56
Day's Volume 232,949
52-Week Range 1.00 - 8.35

More Stats

Market Cap 39.62M
Enterprise Value 24.32M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 9.03M
Float 6.07M
EPS (basic) -8.23
EPS (diluted) -10.33
FCF / Share -2.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 227,872
Short Ratio 0.11
Short % of Float 4.59%
Beta 1.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.23
Revenue n/a
Operating Income -10.04M
Net Income -8.96M
Free Cash Flow -10.20M
Net Cash 15.30M
Net Cash / Share 1.70
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -40.24%
ROE -92.32%
ROIC -234.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.00*
(196.13% upside)
Low
12.0
Current: $4.39
High
14.0
Target: 13.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-7.77-14.59-10.52-20.81-13.96-1.67
Net Income-6.72-9.45-7.51-17.00-22.19-5.28
Shares Outstanding2.040.180.140.050.040.02
Earnings Per Share-5.95-97.35-54.58-352.69-571.03-229.53
Operating Cash Flow-7.57-15.65-8.21-16.56-9.67-1.36
Capital Expenditures-0.05---0.01-0.08-0.02
Free Cash Flow-7.62-15.65-8.21-16.56-9.76-1.38
Cash & Equivalents13.922.835.957.404.561.82
Total Debt0.811.44-0.01--
Net Cash / Debt13.121.395.957.394.561.82
Assets20.438.1911.2513.115.382.00
Liabilities4.256.217.5511.791.944.93
Book Value16.191.983.701.323.44-2.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Hepion Pharmaceuticals, Inc.
Country United States
Employees 12
CEO Robert T. Foster

Stock Information

Ticker Symbol HEPA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HEPA

Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.